Arvind Remedies Ltd. announced audited standalone earnings results for the fourth quarter and full year ended March 31, 2013 and audited consolidated earnings results for the full year ended March 31, 2013. For the quarter, the company reported net sales of INR 1,739.827 million compared with INR 1,056.057 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 349.381 million compared with INR 223.555 million for the same period a year ago. Profit from ordinary activities before tax was INR 183.607 million compared with INR 141.567 million for the same period a year ago. Net profit was INR 124.127 million or INR 2.47 per diluted share before and after extraordinary items compared with INR 4.475 million or INR 0.09 per diluted share before and after extraordinary items for the same period a year ago. For the full year, the company reported net sales of INR 6,632.595 million compared with INR 4,365.667 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,211.456 million compared with INR 645.487 million for the same period a year ago. Profit from ordinary activities before tax was INR 625.508 million compared with INR 372.125 million for the same period a year ago. Net profit was INR 406.169 million or INR 8.09 per diluted share before and after extraordinary items compared with INR 194.099 million or INR 4.02 per diluted share before and after extraordinary items for the same period a year ago. For the full year, the consolidated company reported net sales of INR 7,043.597 million compared with INR 4,670.797 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,275.187 million compared with INR 686.530 million for the same period a year ago. Profit from ordinary activities before tax was INR 679.970 million compared with INR 402.648 million for the same period a year ago. Net profit was INR 449.614 million or INR 8.64 per diluted share before and after extraordinary items compared with INR 216.970 million or INR 0.43 per diluted share before and after extraordinary items for the same period a year ago.

Arvind Remedies Ltd. at the board meeting held on May 15, 2013, recommended a dividend of INR 1 per equity share (including 2% special dividend due to Silver Jubilee year) of INR 10 each, subject to the approval of the shareholders in the Annual General Meeting.

Arvind Remedies Ltd, Board Meeting, May 15, 2013. Agenda: To consider the audited standalone earnings results for the fourth quarter and full year ended March 31, 2013 and audited consolidated earnings results for the full year ended March 31, 2013; to consider and recommended a dividend of INR 1 per equity share (including 2% special dividend due to silver jubilee year) of INR 10 each, subject to the approval of the shareholders in the annual general meeting; to approved the demerger of Irungattukottai unit of the company into their wholly owned subsidiary, the company and fixed the appointed date as April 08, 2013; and to authorized Dr. B. Arvind Shah, Managing Director to sign, execute and file necessary applications/ documents/ papers in matters relating to demerger to various statutory authorities including Stock Exchange, High Court etc.